COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection

OBJECTIVE: COVID-19 outcome may be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases (RMD) receiving immunosuppressive therapy. We aimed to investigate whether RMD patients on anti-IL6 therapy prior to SARS-CoV-2 infection have less severe disease and better outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Comarmond, Cloé, Drumez, Elodie, Labreuche, Julien, Hachulla, Eric, Thomas, Thierry, Flipo, René-Marc, Seror, Raphaëlle, Avouac, Jérôme, Balandraud, Nathalie, Desbarbieux, Renaud, Felten, Renaud, Gilson, Mélanie, Guyot, Marie-Hélène, Hittinger-Roux, Ambre, Pham, Thao, Renard, Myriam, Roux, Nicolas, Sobanski, Vincent, Tournadre, Anne, Richez, Christophe, Cacoub, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839461/
https://www.ncbi.nlm.nih.gov/pubmed/36684808
http://dx.doi.org/10.1016/j.jtauto.2023.100190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839461/
https://www.ncbi.nlm.nih.gov/pubmed/36684808
http://dx.doi.org/10.1016/j.jtauto.2023.100190

Ejemplares similares